[go: up one dir, main page]

PE20081846A1 - Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico - Google Patents

Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico

Info

Publication number
PE20081846A1
PE20081846A1 PE2008000062A PE2008000062A PE20081846A1 PE 20081846 A1 PE20081846 A1 PE 20081846A1 PE 2008000062 A PE2008000062 A PE 2008000062A PE 2008000062 A PE2008000062 A PE 2008000062A PE 20081846 A1 PE20081846 A1 PE 20081846A1
Authority
PE
Peru
Prior art keywords
amino
halogen
alkyl
optionally substituted
nicotinic
Prior art date
Application number
PE2008000062A
Other languages
English (en)
Inventor
Palomino Laria Julio Cesar Castro
Sola Montserrat Erra
Toribio Maria Estrella Lozoya
Romero Eloisa Navarro
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200701086A external-priority patent/ES2327372B1/es
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of PE20081846A1 publication Critical patent/PE20081846A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE LOS ACIDOS AMINO-NICOTINICO Y AMINO-ISONICOTINICO DE FORMULA (I), EN DONDE UN G1 ES N O CRc, Y EL OTRO ES CRc; G2 ES N O CRd; R1 ES H, HALOGENO, ALQUILO(C1-C4) O CICLOALQUILO(C3-C8), OPCIONALMENTE SUSTITUIDOS; R2 H, HALOGENO, HIDROXILO, ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO; ENTRE OTROS; RA, RB Y RC SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), OPCIONALMENTE SUSTITUIDOS; ES H, HALOGENO, HIDROXILO, ALQUILO(C1-C4), ALCOXI(C1-C4), CICLOALCOXI(C3-C8), OPCIONALMENTE SUSTITUIDOS; UN G3 O G4 ES N Y EL OTRO ES CH; M ES H O CATION, CON LA CONDICION DE QUE AL MENOS UN RA Y RB SEA H Y G2 SEA CRd, ENTONCES Rd ES ALCOXI OPCIONALMENTE SUSTITUIDO. SON SELECCIONADOS: ACIDO 2-(3-FLUORO-3'-METOXIBIFENIL-4-ILAMINO)NICOTINICO, 3-(3'-ETOXI-3-FLUOROBIFENIL-4-ILAMINO)ISONICOTINATO DE LITIO, ENTRE OTROS. ESTOS COMPUESTOS SON INHIBIDORES DE LA DIHIDROOROTATO DESHIDROGENASA (DHODH), POR LO QUE SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES, DEL SISTEMA INMUNE E INFLAMATORIAS, TRASTORNOS DESTRUCTIVOS DE LOS HUESOS, ENFERMEDADES NEOPLASICAS, ENTRE OTRAS
PE2008000062A 2006-12-22 2008-01-02 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico PE20081846A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200603250A ES2319596B1 (es) 2006-12-22 2006-12-22 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES200701086A ES2327372B1 (es) 2007-04-23 2007-04-23 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.

Publications (1)

Publication Number Publication Date
PE20081846A1 true PE20081846A1 (es) 2008-12-27

Family

ID=39319647

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000062A PE20081846A1 (es) 2006-12-22 2008-01-02 Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico

Country Status (31)

Country Link
US (2) US8258308B2 (es)
EP (1) EP2121614B1 (es)
JP (1) JP5318776B2 (es)
KR (1) KR101435233B1 (es)
CN (1) CN101589025B (es)
AR (1) AR064444A1 (es)
AU (1) AU2007338321B2 (es)
BR (1) BRPI0717697B1 (es)
CA (1) CA2674512C (es)
CL (1) CL2007003666A1 (es)
CY (1) CY1113687T1 (es)
DK (1) DK2121614T3 (es)
EC (1) ECSP099395A (es)
ES (2) ES2319596B1 (es)
HR (1) HRP20120697T1 (es)
IL (1) IL199188A (es)
ME (1) ME01475B (es)
MX (1) MX2009006408A (es)
MY (1) MY153393A (es)
NO (1) NO341991B1 (es)
NZ (1) NZ577017A (es)
PE (1) PE20081846A1 (es)
PL (1) PL2121614T3 (es)
PT (1) PT2121614E (es)
RS (1) RS52514B (es)
RU (1) RU2469024C2 (es)
SI (1) SI2121614T1 (es)
TW (1) TWI405572B (es)
UY (1) UY30794A1 (es)
WO (1) WO2008077639A1 (es)
ZA (1) ZA200903335B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SG174054A1 (en) 2006-05-04 2011-09-29 Boehringer Ingelheim Int Polymorphs
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2327372B1 (es) * 2007-04-23 2010-08-24 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
WO2010052027A1 (en) * 2008-11-07 2010-05-14 4Sc Ag Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2226323A1 (en) 2009-02-27 2010-09-08 Almirall, S.A. New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228367A1 (en) * 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
TWI530286B (zh) 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
EP2314577A1 (en) * 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2360158A1 (en) 2010-02-18 2011-08-24 Almirall, S.A. Pyrazole derivatives as jak inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2380890A1 (en) 2010-04-23 2011-10-26 Almirall, S.A. New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en) 2010-06-15 2011-12-21 Almirall, S.A. Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2444088A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2455081A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2455080A1 (en) 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
US10016402B2 (en) 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2594271A1 (en) 2011-11-21 2013-05-22 Almirall, S.A. 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis.
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
HRP20190723T1 (hr) * 2012-10-31 2019-06-14 Fujifilm Toyama Chemical Co., Ltd. Novi derivat amina ili njegova sol kao inhibitor tnf alfa
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
WO2015077535A2 (en) 2013-11-22 2015-05-28 Genzyme Corporation Novel methods for treating neurodegenerative diseases
WO2015154820A1 (en) 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
EP3139914B1 (en) 2014-05-08 2023-07-26 Kiora Pharmaceuticals GmbH Compounds for treating ophthalmic diseases and disorders
WO2016200778A1 (en) * 2015-06-08 2016-12-15 Children's Medical Center Corporation Methods for treatment of melanoma
WO2016202800A1 (en) 2015-06-16 2016-12-22 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
WO2018136010A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
WO2018157843A1 (zh) * 2017-03-02 2018-09-07 中国科学院上海药物研究所 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
WO2018160138A1 (en) 2017-03-02 2018-09-07 Aslan Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
JP6978251B2 (ja) * 2017-03-03 2021-12-08 アスラン ファーマシューティカルズ ピーティーイー リミテッド がん治療
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2019170848A1 (en) 2018-03-09 2019-09-12 Panoptes Pharma Ges.M.B.H. Ophthalmic formulation
JP7126556B2 (ja) 2018-09-28 2022-08-26 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
US20220364065A1 (en) * 2018-12-21 2022-11-17 National University Corporation Hokkaido University Composition for removing pluripotent stem cells and method of removing pluripotent stem cells
EP3750892A1 (en) 2019-06-14 2020-12-16 Yerevan State University Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses
JP7288074B2 (ja) 2019-10-31 2023-06-06 富士フイルム株式会社 ピラジン誘導体またはその塩およびその利用
WO2022025174A1 (ja) * 2020-07-30 2022-02-03 富士フイルム株式会社 含窒素複素環化合物またはその塩、その利用、およびその中間体
KR20230116779A (ko) * 2020-10-15 2023-08-04 아슬란 파마슈티컬스 피티이 엘티디 디히드로오로테이트 헤하이드로즈네이즈(dhodh) 저해제를 이용한 자가면역 질환의 치료
CN116940359A (zh) * 2020-10-15 2023-10-24 亚狮康私人有限公司 用二氢乳清酸脱氢酶（dhodh）抑制剂治疗自身免疫病
EP4362968A4 (en) * 2021-06-30 2025-07-23 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD47-SIRPA THERAPEUTIC AGENT
EP4472948A2 (en) * 2022-01-31 2024-12-11 New Frontier Bio, Inc. Nicotinate and nicotinamide riboside-based compounds and derivatives thereof
CN118984822A (zh) * 2022-02-03 2024-11-19 亚狮康私人有限公司 Dhodh抑制剂多晶型物
WO2025215126A1 (en) 2024-04-12 2025-10-16 Immunic Ag Synthesis of vidofludimus and its calcium salt

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US529490A (en) * 1894-11-20 hegg-em
EP0040896B1 (en) * 1978-08-22 1984-04-25 Sumitomo Chemical Company, Limited Synthesis of amides
JPH05331163A (ja) * 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
ATE208772T1 (de) * 1993-10-01 2001-11-15 Novartis Erfind Verwalt Gmbh Pharmacologisch wirksame pyridinderivate und verfahren zu deren herstellung
CZ294700B6 (cs) 1995-06-21 2005-02-16 Sofotec Gmbh & Co. Kg Pouzdro na farmaceutický prášek pro práškové inhalátory
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
EA004632B1 (ru) * 1999-06-10 2004-06-24 Уорнер-Ламберт Компани Ингибиторы агрегации амилоидных белков, их применение (варианты), композиция на их основе и способ визуализации амилоидных отложений
WO2002080897A1 (en) 2001-04-05 2002-10-17 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PE20030120A1 (es) 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
WO2003006424A1 (en) * 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
AU2003300530A1 (en) * 2002-12-23 2004-07-14 4Sc Ag Dhodh-inhibitors and method for their identification
WO2004056746A1 (en) 2002-12-23 2004-07-08 4Sc Ag Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
AU2005257862A1 (en) 2004-05-21 2006-01-05 The Uab Research Foundation Compositions and methods relating to pyrimidine synthesis inhibitors
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
EP1804782A1 (en) 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
PT1802579E (pt) * 2004-10-20 2014-02-17 Merck Serono Sa Derivados da 3-arilaminopiridina
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
KR20090110931A (ko) 2007-02-06 2009-10-23 첼시 쎄라퓨틱스, 인코포레이티드 신규한 화합물, 이의 제조방법 및 이의 용도
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
JP5318776B2 (ja) 2013-10-16
ME01475B (me) 2014-04-20
MY153393A (en) 2015-02-13
HK1133014A1 (en) 2010-03-12
NO341991B1 (no) 2018-03-12
AU2007338321B2 (en) 2012-01-19
TWI405572B (zh) 2013-08-21
RS52514B (sr) 2013-04-30
TW200833332A (en) 2008-08-16
US8691852B2 (en) 2014-04-08
RU2009127847A (ru) 2011-01-27
BRPI0717697B1 (pt) 2022-05-03
RU2469024C2 (ru) 2012-12-10
PL2121614T3 (pl) 2012-11-30
CL2007003666A1 (es) 2008-07-04
CN101589025A (zh) 2009-11-25
US20100074898A1 (en) 2010-03-25
AU2007338321A1 (en) 2008-07-03
AR064444A1 (es) 2009-04-01
KR20090090352A (ko) 2009-08-25
CA2674512C (en) 2015-09-08
HRP20120697T1 (hr) 2012-09-30
ES2319596B1 (es) 2010-02-08
NO20092380L (no) 2009-07-14
US8258308B2 (en) 2012-09-04
PT2121614E (pt) 2012-08-31
ECSP099395A (es) 2009-07-31
JP2010513362A (ja) 2010-04-30
WO2008077639A1 (en) 2008-07-03
SI2121614T1 (sl) 2012-10-30
EP2121614B1 (en) 2012-06-20
CN101589025B (zh) 2012-05-30
IL199188A (en) 2014-06-30
UY30794A1 (es) 2008-05-31
DK2121614T3 (da) 2012-09-17
KR101435233B1 (ko) 2014-08-28
CA2674512A1 (en) 2008-07-03
ZA200903335B (en) 2010-06-30
MX2009006408A (es) 2009-06-23
US20120294854A1 (en) 2012-11-22
ES2319596A1 (es) 2009-05-08
ES2389785T3 (es) 2012-10-31
EP2121614A1 (en) 2009-11-25
BRPI0717697A2 (pt) 2016-03-22
NZ577017A (en) 2011-12-22
CY1113687T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
PE20081846A1 (es) Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
AU2019362747A1 (en) PFKFB3 inhibitors and their uses
AR039566A1 (es) Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
ES2865182T3 (es) Inhibidor de URAT1
PE20211640A1 (es) INHIBICION DE LA INTEGRINA xvß6
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
PE20040290A1 (es) Derivados de piperidinas- benzodiazepinas como antagonistas del cgrp
NO20071843L (no) Substituerte anilinderivater
PE20091407A1 (es) Antagonistas de aminoalquilbifenilo n,n-disubstituidos de receptores de prostaglandina d2
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
PE20030535A1 (es) Derivados de naftiridin como inhibidores de isoenzima fosfodiesterasa de nucleotido ciclica
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
NO20064599L (no) Substituerte morfolin- og tiomorfolinderivater
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
PA8463501A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
AR076551A1 (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi
BR0313341A (pt) Método para a preparação de uma oxazinona fundida e método para a preparação de um composto de fórmula iii
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20090757A1 (es) Formulaciones que contienen triazinonas y hierro
PH12014500997B1 (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
ECSP077160A (es) Nuevos d-homo-estra-1,3,5(10)-trienos sustituidos en la posición 2 como inhibidores de 17 -hidroxiesteroide deshidrogenasa tipo 1

Legal Events

Date Code Title Description
FG Grant, registration